ANAB
AnaptysBio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.79B
P/E Ratio
—
EPS
$-0.46
Beta
0.41
52W High
$68.39
52W Low
$15.40
50-Day MA
$56.27
200-Day MA
$38.03
Dividend Yield
—
Profit Margin
-5.64%
Forward P/E
—
PEG Ratio
0.00
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $234.60M |
| Gross Profit (TTM) | $98.63M |
| EBITDA | $48.45M |
| Operating Margin | 61.80% |
| Return on Equity | -24.50% |
| Return on Assets | 7.06% |
| Revenue/Share (TTM) | $8.16 |
| Book Value | $1.33 |
| Price-to-Book | 44.56 |
| Price-to-Sales (TTM) | 7.65 |
| EV/Revenue | 5.8 |
| EV/EBITDA | 19.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.10% |
| Shares Outstanding | $28.75M |
| Float | $17.26M |
| % Insiders | 5.86% |
| % Institutions | 100.99% |
Analyst Ratings
Consensus ($79.91 target)
3
Strong Buy9
Buy1
HoldData last updated: 4/7/2026